Skip to content
AnalystLens

Cigna Group 8-K Report, Financial Results (Feb 2, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 2, 2024
Period End
February 2, 2024
Security
CI
In the record · 2018–202610-K810-Q238-K136

CI filed 8 annual reports (10-K), 23 quarterly reports (10-Q) and 136 current reports (8-K) between 2018 and 2026.

  1. Deal closed8-K · Feb ’19Feb ’19
  2. Material agreement8-K · Apr ’21Apr ’21
  3. Leadership change8-K · May ’23May ’23
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed February 2, 2024. Cited figures are marked; the original filing is the authoritative source.

The Cigna Group's February 2, 2024 Form 8-K (Item 2.02) furnishes its fourth-quarter and full-year 2023 earnings release.

Full-year 2023 total revenues were $195.3 billiona, up about 8% from $180.5 billion, and GAAP shareholders' net income was $5.2 billion, or $17.39 per share, down from $6.7 billion, or $21.41 per share, in 2022. The decline was driven largely by special items, including a $1.4 billion after-tax loss on the sale of businesses in 2023 versus a gain in 2022. Adjusted income from operations, the metric management emphasizes, rose to $7.4 billion, or $25.09 per share, from $7.3 billion, or $23.36 per share.

Fourth-quarter adjusted EPS of $6.79b grew about 35% year over year, reflecting strong contributions from both segments. Segment performance was broadly positive. Evernorth Health Services' full-year adjusted pre-tax income grew 5% to $6.4 billion on 9% adjusted revenue growth, although margins compressed modestly to 4.2% as management invested in technology and client onboarding.

Cigna Healthcare was the standout, with full-year adjusted pre-tax income up 9% to $4.5 billionc. Its medical care ratio improved to 81.3% from 81.7%, aided by affordability initiatives and pricing discipline, and total medical customers reached 19.8 million, up 10%. Corporate and other operations losses widened to $1.6 billion, mainly because income from divested businesses no longer contributes.

Looking ahead, management guided 2024 adjusted income from operations to at least $8.025 billiond, or at least $28.25 per share, and adjusted revenues to at least $235 billion. The board also raised the quarterly dividend 14% to $1.40 per share. Investors should weigh the strong operating momentum and capital return against the sizable GAAP charges in 2023, the continued reliance on adjusted (non-GAAP) metrics, and the forward-looking risks flagged in the release, including medical cost trends, pharmacy pricing pressure, and regulatory exposure in government programs.

02—Key points

Key Highlights

  1. Full-year 2023 adjusted income from operations rose to $7.4 billion ($25.09 per share) from $7.3 billion ($23.36 per share), while GAAP shareholders' net income fell to $5.2 billion ($17.39 per share) from $6.7 billion.
  2. Fourth-quarter adjusted income from operations increased about 30% to $2.0 billion ($6.79 per share), driven by strong contributions from Evernorth and Cigna Healthcare.
  3. Cigna Healthcare's full-year MCR improved to 81.3% from 81.7%, and adjusted pre-tax income rose to $4.5 billion from $4.1 billion.
  4. Evernorth's full-year adjusted revenues grew 9% to $153.5 billion, though its pre-tax margin eased to 4.2% from 4.4% due to technology investments.
  5. 2024 guidance calls for adjusted income from operations of at least $8.025 billion ($28.25 per share) and adjusted revenues of at least $235 billion.
  6. The quarterly dividend was raised 14% to $1.40 per share, and the company repurchased 7.8 million shares for about $2.3 billion in 2023.
  7. GAAP 2023 results included a roughly $1.4 billion after-tax loss on the sale of businesses and a charge for an organizational efficiency plan, which weighed on reported earnings.

03—Questions

Frequently Asked Questions

  1. Why did GAAP net income fall in 2023 even though adjusted earnings grew?

    GAAP shareholders' net income fell to $5.2 billion ($17.39 per share) from $6.7 billion ($21.41 per share) in 2022. The main reason was a $1.4 billion after-tax loss on the sale of businesses in 2023, compared with a gain on sales in 2022, along with amortization of acquired intangibles and an organizational efficiency charge. Adjusted income from operations excludes these items, which is why it rose to $7.4 billion.

  2. What is driving the 2024 earnings outlook?

    Management projects adjusted income from operations of at least $8.025 billion, or at least $28.25 per share, on adjusted revenues of at least $235 billion. Cigna Healthcare is expected to contribute at least $4.75 billion in pre-tax adjusted income, with a medical care ratio of 81.7% to 82.7%, and Evernorth at least $7.0 billion. The outlook includes expected share repurchases and dividends.

  3. How healthy is Cigna Healthcare's underlying performance?

    Performance improved. The full-year MCR fell to 81.3% from 81.7%, supported by affordability initiatives, pricing execution, and favorable stop-loss results. Total medical customers grew 10% to 19.8 million, and favorable prior-year reserve development was $279 million pre-tax. Investors should note that the MCR guidance for 2024 is somewhat higher than the 2023 result.

  4. Is the dividend increase sustainable, and how much capital is being returned?

    The board declared a quarterly dividend of $1.40 per share, a 14% increase from $1.23, payable March 21, 2024. Management projects about $1.55 billion in 2024 shareholder dividends. In 2023, the company repurchased 7.8 million shares for about $2.3 billion, and debt-to-capitalization improved to 40.1% from 41.0% a year earlier. Dividends remain subject to board approval and the company's financial position.

04—Continue

← View all 8-K filings